We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Evotec AG has entered a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat diabetes and obesity, as well as co-morbidities such as nonalcoholic steatohepatitis (NASH), cardiovascular diseases, and diabetic